RecruitingNCT05909501

Assessment of Geriatric Evaluations Impact on New AML Guidance

AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

100 participants

Start Date

Oct 25, 2023

Study Type

OBSERVATIONAL

Conditions

AML, Adult

Summary

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether a comprehensive geriatric evaluation (a full assessment of an older adult's physical, cognitive, and functional health) can help doctors make better, more personalized treatment decisions for older adults newly diagnosed with AML (acute myeloid leukemia) — a fast-moving blood cancer. **You may be eligible if...** - You are 50 or older with a new AML diagnosis - You are being considered for a new treatment approach - You are in adequate health to participate (performance status 0, 1, or 2) **You may NOT be eligible if...** - You cannot understand or sign a written informed consent - You cannot fill out questionnaires on your own and have no one to help you Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.